Share Price and Basic Stock Data
Last Updated: January 7, 2026, 9:27 am
| PEG Ratio | -5.32 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Gufic BioSciences Ltd operates within the pharmaceuticals sector, focusing on manufacturing and marketing a range of pharmaceutical products. The company’s revenue trajectory has shown significant fluctuations over the years. For the financial year ending March 2025, Gufic reported sales of ₹820 Cr, an increase from ₹691 Cr in the previous year, reflecting a growth trend. In the trailing twelve months (TTM), revenues stood at ₹870 Cr, indicating a robust performance in recent quarters. Quarterly sales data reveals a consistent upward movement, with revenues reaching ₹215 Cr in September 2023 and projected to rise to ₹230 Cr by September 2025. This positive trend is supported by a strong demand for pharmaceutical products and a strategic focus on expanding its product portfolio, enabling Gufic to adapt to market dynamics effectively. The company’s operating profit margin (OPM) has hovered around 17% in recent years, indicating a stable operational efficiency despite the variability in sales figures.
Profitability and Efficiency Metrics
Gufic BioSciences Ltd’s profitability metrics have shown some volatility in recent quarters. The net profit for the financial year ending March 2025 was recorded at ₹70 Cr, a decline from ₹80 Cr in the previous year. The operating profit for the same period was ₹136 Cr, demonstrating an operating profit margin of 17%, which is slightly lower than the previous year’s 20%. The company’s return on equity (ROE) stands at 12.3%, while the return on capital employed (ROCE) is reported at 13.2%. These figures reflect a solid performance compared to industry averages, although the declining trend in net profit raises concerns. Gufic’s cash conversion cycle (CCC) has stretched to 197 days, indicating potential inefficiencies in managing working capital. The interest coverage ratio (ICR) at 5.70x remains healthy, suggesting that Gufic can adequately cover its interest expenses, although close monitoring of debt levels is crucial moving forward.
Balance Sheet Strength and Financial Ratios
Gufic BioSciences Ltd’s balance sheet reveals a mixed picture of financial health. As of March 2025, total assets were reported at ₹1,170 Cr, supported by reserves of ₹619 Cr and borrowings amounting to ₹369 Cr. This indicates a manageable debt-to-equity ratio of 0.51x, showcasing a relatively low reliance on debt financing. However, the company’s total liabilities have increased significantly, from ₹861 Cr in March 2023 to ₹1,170 Cr in March 2025, raising concerns about future obligations. The book value per share has risen to ₹59.94, up from ₹53.11 in the previous year, reflecting the company’s efforts to enhance shareholder value. Financial ratios such as the current ratio at 1.61x portray a sound liquidity position, while the quick ratio of 1.05x indicates that Gufic can meet its short-term liabilities. The company has maintained a price-to-book value ratio of 5.61x, higher than typical sector ranges, suggesting that the market may be pricing in future growth potential.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Gufic BioSciences Ltd demonstrates a strong promoter commitment, with promoters holding 72.50% of the equity as of September 2025. The presence of foreign institutional investors (FIIs) remains minimal at 0.33%, while domestic institutional investors (DIIs) have increased their stake to 3.66%. The public holding stands at 23.51%, indicating a diversified ownership structure. This pattern suggests that while there is significant confidence among promoters, the low FII participation may reflect cautious sentiment regarding the stock’s growth prospects. The number of shareholders has decreased to 31,420, indicating potential consolidation among retail investors. The declining trend in net profit and fluctuations in quarterly earnings may have contributed to this reduced interest among the broader public, although the increasing DII stake could signal a belief in the company’s long-term potential.
Outlook, Risks, and Final Insight
Looking ahead, Gufic BioSciences Ltd faces both opportunities and risks. On the positive side, the company is well-positioned to capitalize on the growing demand for pharmaceutical products, particularly as it expands its product offerings and enhances operational efficiency. However, risks such as rising input costs, regulatory challenges, and the need to manage a lengthy cash conversion cycle may hinder profitability. Additionally, fluctuations in net profit and a high price-to-book ratio could lead to volatility in share price performance. To navigate these challenges, Gufic must focus on improving operational efficiencies and managing debt levels effectively. If the company can successfully execute its growth strategies while maintaining financial discipline, it could enhance shareholder value significantly in the coming years. Conversely, failure to address these risks may impact investor confidence and overall market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 131 Cr. | 104 | 214/84.3 | 29.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,541 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.9 Cr. | 44.3 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 55.8 Cr. | 38.1 | 39.1/17.0 | 133 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,894.68 Cr | 1,156.20 | 54.51 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 175 | 177 | 173 | 195 | 215 | 202 | 195 | 203 | 204 | 208 | 205 | 227 | 230 |
| Expenses | 142 | 143 | 141 | 160 | 176 | 165 | 161 | 167 | 166 | 174 | 178 | 195 | 195 |
| Operating Profit | 33 | 34 | 32 | 35 | 39 | 36 | 34 | 36 | 39 | 34 | 27 | 32 | 36 |
| OPM % | 19% | 19% | 19% | 18% | 18% | 18% | 18% | 18% | 19% | 16% | 13% | 14% | 16% |
| Other Income | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 1 | 2 |
| Interest | 2 | 2 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 8 | 9 | 10 |
| Depreciation | 5 | 6 | 6 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 8 | 8 | 8 |
| Profit before tax | 27 | 27 | 24 | 28 | 31 | 30 | 27 | 28 | 29 | 26 | 11 | 16 | 21 |
| Tax % | 26% | 25% | 24% | 26% | 25% | 25% | 26% | 26% | 26% | 26% | 26% | 26% | 27% |
| Net Profit | 20 | 20 | 18 | 21 | 23 | 22 | 20 | 21 | 22 | 19 | 8 | 12 | 15 |
| EPS in Rs | 2.08 | 2.10 | 1.87 | 2.13 | 2.39 | 2.22 | 2.00 | 2.08 | 2.17 | 1.93 | 0.79 | 1.20 | 1.49 |
Last Updated: January 1, 2026, 1:46 pm
Below is a detailed analysis of the quarterly data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 230.00 Cr.. The value appears strong and on an upward trend. It has increased from 227.00 Cr. (Jun 2025) to 230.00 Cr., marking an increase of 3.00 Cr..
- For Expenses, as of Sep 2025, the value is 195.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 195.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 36.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Jun 2025) to 36.00 Cr., marking an increase of 4.00 Cr..
- For OPM %, as of Sep 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 14.00% (Jun 2025) to 16.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Jun 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 10.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.00 Cr. (Jun 2025) to 10.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 8.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Jun 2025) to 21.00 Cr., marking an increase of 5.00 Cr..
- For Tax %, as of Sep 2025, the value is 27.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Jun 2025) to 27.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Jun 2025) to 15.00 Cr., marking an increase of 3.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.49. The value appears strong and on an upward trend. It has increased from 1.20 (Jun 2025) to 1.49, marking an increase of 0.29.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 148 | 201 | 245 | 306 | 351 | 379 | 488 | 779 | 691 | 807 | 820 | 870 |
| Expenses | 109 | 134 | 181 | 222 | 267 | 305 | 327 | 404 | 631 | 556 | 657 | 683 | 741 |
| Operating Profit | 12 | 14 | 20 | 23 | 39 | 46 | 52 | 84 | 148 | 135 | 150 | 136 | 129 |
| OPM % | 10% | 10% | 10% | 9% | 13% | 13% | 14% | 17% | 19% | 20% | 19% | 17% | 15% |
| Other Income | 1 | 1 | 1 | 1 | 4 | 4 | 6 | 4 | 3 | 3 | -0 | 4 | 5 |
| Interest | 4 | 4 | 6 | 6 | 9 | 10 | 14 | 14 | 5 | 8 | 17 | 25 | 32 |
| Depreciation | 2 | 4 | 4 | 4 | 4 | 5 | 14 | 16 | 19 | 22 | 17 | 21 | 28 |
| Profit before tax | 6 | 7 | 10 | 14 | 30 | 35 | 30 | 58 | 127 | 107 | 116 | 94 | 74 |
| Tax % | 32% | 36% | 29% | 37% | 45% | 38% | 25% | 23% | 24% | 25% | 26% | 26% | |
| Net Profit | 4 | 4 | 7 | 9 | 16 | 22 | 23 | 44 | 96 | 80 | 86 | 70 | 54 |
| EPS in Rs | 0.55 | 0.54 | 0.95 | 1.17 | 2.13 | 2.82 | 2.92 | 5.68 | 9.89 | 8.22 | 8.59 | 6.97 | 5.41 |
| Dividend Payout % | 9% | 9% | 5% | 4% | 2% | 2% | 2% | 2% | 1% | 1% | 1% | 1% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 75.00% | 28.57% | 77.78% | 37.50% | 4.55% | 91.30% | 118.18% | -16.67% | 7.50% | -18.60% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -46.43% | 49.21% | -40.28% | -32.95% | 86.76% | 26.88% | -134.85% | 24.17% | -26.10% |
Gufic BioSciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 17% |
| 3 Years: | 2% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 33% |
| 5 Years: | 25% |
| 3 Years: | -10% |
| TTM: | -29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 35% |
| 3 Years: | 16% |
| 1 Year: | -7% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 22% |
| 3 Years: | 18% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 5:30 am
Balance Sheet
Last Updated: December 4, 2025, 1:19 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 18 | 19 | 26 | 30 | 46 | 68 | 120 | 164 | 259 | 338 | 523 | 591 | 619 |
| Borrowings | 33 | 33 | 43 | 57 | 80 | 98 | 126 | 62 | 64 | 334 | 333 | 336 | 369 |
| Other Liabilities | 52 | 67 | 75 | 84 | 104 | 106 | 152 | 157 | 188 | 179 | 227 | 232 | 271 |
| Total Liabilities | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
| Fixed Assets | 30 | 25 | 22 | 22 | 23 | 24 | 83 | 100 | 115 | 160 | 159 | 506 | 495 |
| CWIP | 0 | 0 | 0 | 0 | 2 | 10 | 31 | 13 | 41 | 170 | 307 | 22 | 24 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 3 |
| Other Assets | 81 | 102 | 130 | 156 | 213 | 245 | 294 | 279 | 365 | 531 | 625 | 639 | 747 |
| Total Assets | 111 | 127 | 152 | 178 | 238 | 280 | 408 | 392 | 521 | 861 | 1,093 | 1,170 | 1,268 |
Below is a detailed analysis of the balance sheet data for Gufic BioSciences Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.00 Cr..
- For Reserves, as of Sep 2025, the value is 619.00 Cr.. The value appears strong and on an upward trend. It has increased from 591.00 Cr. (Mar 2025) to 619.00 Cr., marking an increase of 28.00 Cr..
- For Borrowings, as of Sep 2025, the value is 369.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 336.00 Cr. (Mar 2025) to 369.00 Cr., marking an increase of 33.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 271.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 232.00 Cr. (Mar 2025) to 271.00 Cr., marking an increase of 39.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 495.00 Cr.. The value appears to be declining and may need further review. It has decreased from 506.00 Cr. (Mar 2025) to 495.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 24.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 747.00 Cr.. The value appears strong and on an upward trend. It has increased from 639.00 Cr. (Mar 2025) to 747.00 Cr., marking an increase of 108.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,268.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,170.00 Cr. (Mar 2025) to 1,268.00 Cr., marking an increase of 98.00 Cr..
Notably, the Reserves (619.00 Cr.) exceed the Borrowings (369.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -21.00 | -19.00 | -23.00 | -34.00 | -41.00 | -52.00 | -74.00 | 22.00 | 84.00 | -199.00 | -183.00 | -200.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 85 | 82 | 102 | 78 | 97 | 107 | 103 | 93 | 71 | 109 | 149 | 140 |
| Inventory Days | 144 | 165 | 180 | 190 | 238 | 190 | 249 | 138 | 102 | 202 | 188 | 211 |
| Days Payable | 176 | 223 | 188 | 132 | 192 | 157 | 238 | 162 | 125 | 143 | 156 | 155 |
| Cash Conversion Cycle | 54 | 25 | 94 | 136 | 143 | 141 | 114 | 69 | 48 | 167 | 181 | 197 |
| Working Capital Days | 20 | 4 | 18 | 14 | 26 | 40 | 17 | 63 | 50 | 68 | 97 | 93 |
| ROCE % | 17% | 18% | 24% | 24% | 33% | 30% | 21% | 29% | 46% | 23% | 17% | 13% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Multicap Fund | 1,480,998 | 0.33 | 52.67 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 1,000,000 | 0.86 | 35.57 | 1,000,000 | 2025-04-22 17:25:34 | 0% |
| ICICI Prudential Smallcap Fund | 446,517 | 0.19 | 15.88 | 441,293 | 2025-12-15 09:10:00 | 1.18% |
| Bank of India Small Cap Fund | 348,463 | 0.63 | 12.39 | N/A | N/A | N/A |
| ICICI Prudential ELSS Tax Saver Fund | 74,008 | 0.02 | 2.63 | N/A | N/A | N/A |
| ICICI Prudential Bharat Consumption Fund | 32,021 | 0.03 | 1.14 | 4,993 | 2025-12-15 09:10:00 | 541.32% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 1.00 | 1.00 |
| Basic EPS (Rs.) | 6.95 | 8.74 |
| Diluted EPS (Rs.) | 6.95 | 8.74 |
| Cash EPS (Rs.) | 9.05 | 10.29 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 59.94 | 53.11 |
| Revenue From Operations / Share (Rs.) | 81.75 | 80.44 |
| PBDIT / Share (Rs.) | 13.93 | 14.76 |
| PBIT / Share (Rs.) | 11.83 | 13.07 |
| PBT / Share (Rs.) | 9.39 | 11.54 |
| Net Profit / Share (Rs.) | 6.95 | 8.59 |
| NP After MI And SOA / Share (Rs.) | 6.95 | 8.59 |
| PBDIT Margin (%) | 17.04 | 18.35 |
| PBIT Margin (%) | 14.47 | 16.24 |
| PBT Margin (%) | 11.48 | 14.33 |
| Net Profit Margin (%) | 8.49 | 10.67 |
| NP After MI And SOA Margin (%) | 8.49 | 10.67 |
| Return on Networth / Equity (%) | 11.58 | 16.17 |
| Return on Capital Employeed (%) | 15.17 | 18.18 |
| Return On Assets (%) | 5.95 | 7.88 |
| Long Term Debt / Equity (X) | 0.21 | 0.28 |
| Total Debt / Equity (X) | 0.51 | 0.59 |
| Asset Turnover Ratio (%) | 0.72 | 0.00 |
| Current Ratio (X) | 1.61 | 1.61 |
| Quick Ratio (X) | 1.05 | 1.08 |
| Inventory Turnover Ratio (X) | 3.93 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 1.43 | 1.12 |
| Dividend Payout Ratio (CP) (%) | 1.10 | 0.93 |
| Earning Retention Ratio (%) | 98.57 | 98.88 |
| Cash Earning Retention Ratio (%) | 98.90 | 99.07 |
| Interest Coverage Ratio (X) | 5.70 | 9.64 |
| Interest Coverage Ratio (Post Tax) (X) | 3.84 | 6.61 |
| Enterprise Value (Cr.) | 3655.21 | 3142.92 |
| EV / Net Operating Revenue (X) | 4.46 | 3.90 |
| EV / EBITDA (X) | 26.16 | 21.23 |
| MarketCap / Net Operating Revenue (X) | 4.12 | 3.52 |
| Retention Ratios (%) | 98.56 | 98.87 |
| Price / BV (X) | 5.61 | 5.33 |
| Price / Net Operating Revenue (X) | 4.12 | 3.52 |
| EarningsYield | 0.02 | 0.03 |
After reviewing the key financial ratios for Gufic BioSciences Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Diluted EPS (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.74 (Mar 24) to 6.95, marking a decrease of 1.79.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.05. This value is within the healthy range. It has decreased from 10.29 (Mar 24) to 9.05, marking a decrease of 1.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 59.94. It has increased from 53.11 (Mar 24) to 59.94, marking an increase of 6.83.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 81.75. It has increased from 80.44 (Mar 24) to 81.75, marking an increase of 1.31.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.93. This value is within the healthy range. It has decreased from 14.76 (Mar 24) to 13.93, marking a decrease of 0.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.83. This value is within the healthy range. It has decreased from 13.07 (Mar 24) to 11.83, marking a decrease of 1.24.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.39. This value is within the healthy range. It has decreased from 11.54 (Mar 24) to 9.39, marking a decrease of 2.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 6.95. This value is within the healthy range. It has decreased from 8.59 (Mar 24) to 6.95, marking a decrease of 1.64.
- For PBDIT Margin (%), as of Mar 25, the value is 17.04. This value is within the healthy range. It has decreased from 18.35 (Mar 24) to 17.04, marking a decrease of 1.31.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has decreased from 16.24 (Mar 24) to 14.47, marking a decrease of 1.77.
- For PBT Margin (%), as of Mar 25, the value is 11.48. This value is within the healthy range. It has decreased from 14.33 (Mar 24) to 11.48, marking a decrease of 2.85.
- For Net Profit Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.49. This value is within the healthy range. It has decreased from 10.67 (Mar 24) to 8.49, marking a decrease of 2.18.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.58. This value is below the healthy minimum of 15. It has decreased from 16.17 (Mar 24) to 11.58, marking a decrease of 4.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.17. This value is within the healthy range. It has decreased from 18.18 (Mar 24) to 15.17, marking a decrease of 3.01.
- For Return On Assets (%), as of Mar 25, the value is 5.95. This value is within the healthy range. It has decreased from 7.88 (Mar 24) to 5.95, marking a decrease of 1.93.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.28 (Mar 24) to 0.21, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.51. This value is within the healthy range. It has decreased from 0.59 (Mar 24) to 0.51, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.72. It has increased from 0.00 (Mar 24) to 0.72, marking an increase of 0.72.
- For Current Ratio (X), as of Mar 25, the value is 1.61. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.61.
- For Quick Ratio (X), as of Mar 25, the value is 1.05. This value is within the healthy range. It has decreased from 1.08 (Mar 24) to 1.05, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 3.93, marking an increase of 3.93.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 20. It has increased from 1.12 (Mar 24) to 1.43, marking an increase of 0.31.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.10. This value is below the healthy minimum of 20. It has increased from 0.93 (Mar 24) to 1.10, marking an increase of 0.17.
- For Earning Retention Ratio (%), as of Mar 25, the value is 98.57. This value exceeds the healthy maximum of 70. It has decreased from 98.88 (Mar 24) to 98.57, marking a decrease of 0.31.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.90. This value exceeds the healthy maximum of 70. It has decreased from 99.07 (Mar 24) to 98.90, marking a decrease of 0.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.70. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 5.70, marking a decrease of 3.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.84. This value is within the healthy range. It has decreased from 6.61 (Mar 24) to 3.84, marking a decrease of 2.77.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,655.21. It has increased from 3,142.92 (Mar 24) to 3,655.21, marking an increase of 512.29.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.46. This value exceeds the healthy maximum of 3. It has increased from 3.90 (Mar 24) to 4.46, marking an increase of 0.56.
- For EV / EBITDA (X), as of Mar 25, the value is 26.16. This value exceeds the healthy maximum of 15. It has increased from 21.23 (Mar 24) to 26.16, marking an increase of 4.93.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For Retention Ratios (%), as of Mar 25, the value is 98.56. This value exceeds the healthy maximum of 70. It has decreased from 98.87 (Mar 24) to 98.56, marking a decrease of 0.31.
- For Price / BV (X), as of Mar 25, the value is 5.61. This value exceeds the healthy maximum of 3. It has increased from 5.33 (Mar 24) to 5.61, marking an increase of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.12. This value exceeds the healthy maximum of 3. It has increased from 3.52 (Mar 24) to 4.12, marking an increase of 0.60.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
- Net Profit Margin: 8.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.17% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.58% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.84
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 60.5 (Industry average Stock P/E: 54.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.51
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh P Choksi | Chairman & Managing Director |
| Mr. Pranav J Choksi | WholeTime Director & CEO |
| Mr. Pankaj J Gandhi | Whole Time Director |
| Dr. Anu S Auora | Independent Director |
| Mr. Kamal K Seth | Independent Director |
| Mr. Akshya Kumar Mahapatra | Independent Director |
FAQ
What is the intrinsic value of Gufic BioSciences Ltd?
Gufic BioSciences Ltd's intrinsic value (as of 07 January 2026) is ₹373.38 which is 13.84% higher the current market price of ₹328.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,287 Cr. market cap, FY2025-2026 high/low of ₹495/285, reserves of ₹619 Cr, and liabilities of ₹1,268 Cr.
What is the Market Cap of Gufic BioSciences Ltd?
The Market Cap of Gufic BioSciences Ltd is 3,287 Cr..
What is the current Stock Price of Gufic BioSciences Ltd as on 07 January 2026?
The current stock price of Gufic BioSciences Ltd as on 07 January 2026 is ₹328.
What is the High / Low of Gufic BioSciences Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Gufic BioSciences Ltd stocks is ₹495/285.
What is the Stock P/E of Gufic BioSciences Ltd?
The Stock P/E of Gufic BioSciences Ltd is 60.5.
What is the Book Value of Gufic BioSciences Ltd?
The Book Value of Gufic BioSciences Ltd is 62.7.
What is the Dividend Yield of Gufic BioSciences Ltd?
The Dividend Yield of Gufic BioSciences Ltd is 0.03 %.
What is the ROCE of Gufic BioSciences Ltd?
The ROCE of Gufic BioSciences Ltd is 13.2 %.
What is the ROE of Gufic BioSciences Ltd?
The ROE of Gufic BioSciences Ltd is 12.3 %.
What is the Face Value of Gufic BioSciences Ltd?
The Face Value of Gufic BioSciences Ltd is 1.00.